Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Administrative Controls						Print
																Related Pages
										Homeless
**TB Control in Overnight Homeless Facilities Quick Reference Guide**
***Administrative controls are management measures designed to reduce the risk for exposure to persons with infectious TB.***
They work particularly well when homeless facilities in a community collaborate with a TB control program to implement certain core measures, including the following:
Assigning responsibilities for TB infection control to a point-person at each facility;
Conducting TB risk assessments for these facilities;
An example of a risk assessment worksheet for health care facilities that can be modified for use at a homeless facility is available at https://www.cdc.gov/tb/publications/guidelines/pdf/appendixb_092706.pdf
Developing a written TB infection control plan for each facility;
This plan should include procedures for systematically evaluating clients, staff, and volunteers for TB disease and infection (see additional details in the following discussion).
– Evaluations for TB should include regular queries to staff and clients as to whether they have symptoms compatible with TB disease;
– Further medical evaluation should be facilitated for persons with any TB symptoms.
Requiring TB diagnostic evaluations for clients who stay longer than a defined period (e.g., after staying 1 day, 3 days, or 1 week) helps ensure all clients have been evaluated and treated, if necessary, for TB disease and infection.
– This helps minimize exposures to infectious TB within the facility. The grace period during which clients can obtain services without verification of TB diagnostic evaluations can differ by site and should be decided in consultation with the local TB control program.
– Usage of a shared platform for storing test results might facilitate result verification and prevent duplication of efforts.
Maintaining bed maps and tracking bed assignments, ideally in a searchable electronic format (e.g., a spreadsheet) rather than paper records to facilitate contact investigations if a TB case is reported;
Maintaining as much space as possible between beds and positioning beds head to toe to reduce the possibility of transmission;
Posting signs and informational posters for client awareness and cough monitoring(e.g., see https://www.cdc.gov/flu/pdf/protect/cdc_cough.pdf)
Considering use of a cough log to document which persons are coughing, particularly at night, so that they can be referred for medical evaluation (e.g., see https://www.tn.gov/content/dam/tn/health/documents/tuberculosis_guidelines/TB_FJCSheters.pdf) and
Providing ongoing education to staff, volunteers, and clients (see additional details in the following discussion).**Systematic Diagnostic Evaluations for TB Disease and Infection**
***Treating latent TB infection (LTBI) not only prevents future TB cases, but may also interrupt future M. tuberculosis transmission, because it prevents the latent infection from becoming active, contagious TB.***
Two tests for TB infection are available: either (a) the tuberculin skin test (TST) or (b) interferon-gamma release assays (IGRA). Both tests help differentiate persons with *M. tuberculosis* infection from those who do not have it.
*All clients with positive tests for TB infection should be evaluated for TB disease, but a negative test for TB infection does not always exclude the diagnosis of TB disease or LTBI. Decisions regarding patient management should always incorporate epidemiologic, historical, and other clinical information in addition to TST or IGRA results.*
Systematically evaluating facility clients for TB is an essential component of strategies for interrupting potential TB transmission. Screening for TB symptoms can be performed by using a standardized questionnaire that can be completed during client intake by agency staff or volunteers. Clients with symptoms compatible with TB should be separated from others until a medical evaluation for TB disease has been performed. They should remain separated until TB disease has been excluded or the patient is not contagious.
****Strategies for Introducing Systematic Evaluation of Clients for TB**
Homeless
Develop close associations between the TB control program and homeless facilities, even in the absence of a TB outbreak.
Provide continual education (because shelters have high staff and volunteer turnover) about testing for TB infection.
Train facility staff and volunteers in implementing cough monitoring and symptom screening.
Create and implement general infection prevention guidelines for homeless facilities.
Require proof of TB diagnostic evaluations for all staff and volunteers (e.g., annually).**Strategies for Prioritizing Resource Usage**
Ensure those at highest risk for having TB disease or infection are evaluated first (see https://www.cdc.gov/tb/topic/testing/whobetested.htm)
Consider on-site clinical services at the homeless facility for providing testing and screening.
Assist clients in obtaining medical screening if not offered on-site; for example, certain clients are unaware that they have medical insurance, and staff or volunteers can help clients identify and use these resources.**Strategies for Selecting Testing Methods**
Homeless
Coordinate with the TB control program to ensure successful implementation of a TB testing program in a homeless facility.
Use up-to-date recommendations regarding targeted testing and treatment (see https://www.cdc.gov/tb/topic/testing/tbtesttypes.htm or https://www.cdc.gov/tb/topic/treatment/default.htm)
For persons who are at risk for loss to follow-up after a TST (i.e., those who do not return for readings), consider using IGRAs. These tests do not require that clients return to have their test results interpreted (although the results are not back from the laboratory for several days).
Moreover, the same blood draw can be used for other tests (e.g., HIV, syphilis, or hepatitis C).
Consider having local health department personnel on-site at homeless facilities to help with interpretation and communication of test results.
Be aware that IGRAs are also preferred for persons who have received bacille Calmette-Guérin (BCG) vaccination or therapy.
Among facilities with HIV-infected clients, be aware that those clients might not disclose their status and that TSTs are less reliable in identifying TB infection among persons who are immunocompromised.
During an outbreak or in a community with high TB prevalence, including chest radiograph or even sputum collection can improve screening results; however, mass chest radiograph screenings can be expensive and yield limited results.**Strategies for Managing Testing Results**
Homeless
Rather than “decision to treat,” think “intention to engage.” Work individually with clients to decide what works for them. For certain clients, short-term incentives and enablers are motivating; others will need longer-term enablers.
Establish practices that incentivize TB screening and enable treatment. For example, offer vouchers for fast-food restaurants to participants who agree to be screened, or provide TB services (e.g., directly observed treatment [DOT] for LTBI) at meal-delivery sites.
Emphasize the importance of having regular TB screening results to provide a baseline negative result for persons who might become infected later.
Work with primary care clinics and shelters to create a data management system for recording who has been screened.
Ensure the health department has access to the data management system (see section in this report on Homeless Management Information System or HMIS) so that staff can update infection clearances.******TB Education for Staff, Volunteers, and Clients**
Although many persons have heard of TB, few report knowing much about the disease. For this reason, ensuring all staff, volunteers, and clients receive thorough education about TB when they begin working or staying at the facility and on an ongoing basis is crucial. Information shared should include that TB is treatable and curable and that taking certain steps can prevent transmission of TB in homeless facilities.
In collaboration with CDC, the National Health Care for the Homeless Council, United States Interagency Council on Homelessness and other health and social services organizations, the Curry International Tuberculosis Center has developed the “Homelessness and TB Toolkit,” which provides links to many educational resources (see also http://www.currytbcenter.ucsf.edu/products/view/homelessness-and-tb-toolkit)
**Examples include:**
Brochures and Cover-Your-Cough Posters in different languages;
an 18-minute training video, “Shelters and TB: What Staff Need to Know” (2nd ed.);
an online, hour-long course for new staff and volunteers, CDC’s “TB 101”ReferencesMunn MS, Duchin JS, Kay M, Pecha M, Thibault CS, Narita M. Analysis of risk factors for tuberculous infection following exposure at a homeless shelter. *Int J Tuberc Lung Dis* 2015; 19(5):570-5.
Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep 1995;44(No. RR-11):19–34.
Kong P, Tapy J, Calixto P, et al. Skin-test screening and tuberculosis transmission among the homeless. Emerg Infect Dis 2002;8:1280–4. DOI: 10.3201/eid0811.020306.
Rendleman N. Mandated TB screening in a community of homeless people. Am J Prev Med 1999;17:108–13.
Centers for Disease Control and Prevention (CDC)/National Center for HIV/AIDS, Viral Hepatitis, STD, and TB. Core curriculum on tuberculosis: what the clinician should know. 6th ed. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. https://www.cdc.gov/tb/education/corecurr/index.htm
Marks SM, DeLuca N, Walton W. Knowledge, attitudes and risk perceptions about tuberculosis: US National Health Interview Survey. Int J Tuberc Lung Dis 2008;12(11):1261-1267
							
					
							Last Reviewed:  January 23, 2013						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue